Information Provided By: 
Fly News Breaks for September 4, 2019
RDY
Sep 4, 2019 | 11:30 EDT
As previously reported, Credit Suisse analyst Anubhav Aggarwal upgraded Dr. Reddy's to Outperform from Underperform saying that while his previous concerns were high market expectations from Copaxone and Nuvaring, the stock is now at the other extreme, and ignoring the aforementioned drugs, it has a "strong" U.S. pipeline and multiple option values. His analysis shows the company has multiple drugs of $15M-$35M opportunity, which should help its base U.S. sales to continue to grow.
News For RDY From the Last 2 Days
There are no results for your query RDY
